Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine
McINTYRE, P. B. ; RODRIGUES, C. A. ; LENNARD-JONES, J. E. ; BARRISON, I. G. ; WALKER, J. G. ; BARON, J. H. ; THORNTON, P. C.
Oxford, UK : Blackwell Publishing Ltd
Published 1988
Oxford, UK : Blackwell Publishing Ltd
Published 1988
| ISSN: |
1365-2036
|
|---|---|
| Source: |
Blackwell Publishing Journal Backfiles 1879-2005
|
| Topics: |
Medicine
|
| Notes: |
Balsalazide (BSZ) is a pro-drug which releases 5-aminosalicylic acid (5ASA) and 4-aminobenzoyl-β-alanine (an inert carrier) in the colon of various species including man. BSZ was compared with sulphasalazine (SASP) (both 1 g b.d. orally) in the maintenance of remission in patients with ulcerative colitis (UC). Seventy-nine patients (5.3 male, 26 female), mean age 49 years (range 19–79 years), with UC were randomly allocated to either treatment (41 BSZ, 38 SASP) for 6 months. The groups were similar in respect of age, sex, duration and extent of disease. Seven patients defaulted (3 BSZ, 4 SASP) leaving 38 on BSZ and 34 on SASP. Two male patients, both receiving SASP, were withdrawn because of severe side-effects. One of these patients, with an exfoliative rash, was maintained satisfactorily on open BSZ. Remission rates at 6 months (51% BSZ, 63% SASP) were not significantly different (life-table analysis P 〈 0.1). Twelve patients (15%) reported troublesome side-effects (2 BSZ 5%, 10 SASP 26%, P= 0.017 Fisher Exact Test). Mean haemoglobin concentrations, similar on entry, increased after 6 months with BSZ (0.2 g/dl) but decreased with SASP (0.5 g/dl) (P 〈 0.0002). BSZ was not significantly different from SASP in maintaining remission in patients with UC but had fewer side-effects.
|
| Type of Medium: |
Electronic Resource
|
| URL: |
| _version_ | 1798290072972296192 |
|---|---|
| autor | McINTYRE, P. B. RODRIGUES, C. A. LENNARD-JONES, J. E. BARRISON, I. G. WALKER, J. G. BARON, J. H. THORNTON, P. C. |
| autorsonst | BARRISON, I. G. WALKER, J. G. BARON, J. H. THORNTON, P. C. |
| book_url | http://dx.doi.org/10.1111/j.1365-2036.1988.tb00693.x |
| datenlieferant | nat_lic_papers |
| hauptsatz | hsatz_simple |
| identnr | NLZ239091507 |
| insertion_date | 2012-04-17 |
| issn | 1365-2036 |
| journal_name | Alimentary pharmacology & therapeutics |
| materialart | 1 |
| notes | Balsalazide (BSZ) is a pro-drug which releases 5-aminosalicylic acid (5ASA) and 4-aminobenzoyl-β-alanine (an inert carrier) in the colon of various species including man. BSZ was compared with sulphasalazine (SASP) (both 1 g b.d. orally) in the maintenance of remission in patients with ulcerative colitis (UC). Seventy-nine patients (5.3 male, 26 female), mean age 49 years (range 19–79 years), with UC were randomly allocated to either treatment (41 BSZ, 38 SASP) for 6 months. The groups were similar in respect of age, sex, duration and extent of disease. Seven patients defaulted (3 BSZ, 4 SASP) leaving 38 on BSZ and 34 on SASP. Two male patients, both receiving SASP, were withdrawn because of severe side-effects. One of these patients, with an exfoliative rash, was maintained satisfactorily on open BSZ. Remission rates at 6 months (51% BSZ, 63% SASP) were not significantly different (life-table analysis P 〈 0.1). Twelve patients (15%) reported troublesome side-effects (2 BSZ 5%, 10 SASP 26%, P= 0.017 Fisher Exact Test). Mean haemoglobin concentrations, similar on entry, increased after 6 months with BSZ (0.2 g/dl) but decreased with SASP (0.5 g/dl) (P 〈 0.0002). BSZ was not significantly different from SASP in maintaining remission in patients with UC but had fewer side-effects. |
| package_name | Blackwell Publishing |
| publikationsjahr_anzeige | 1988 |
| publikationsjahr_facette | 1988 |
| publikationsjahr_intervall | 8014:1985-1989 |
| publikationsjahr_sort | 1988 |
| publikationsort | Oxford, UK |
| publisher | Blackwell Publishing Ltd |
| reference | 2 (1988), S. 0 |
| search_space | articles |
| shingle_author_1 | McINTYRE, P. B. RODRIGUES, C. A. LENNARD-JONES, J. E. BARRISON, I. G. WALKER, J. G. BARON, J. H. THORNTON, P. C. |
| shingle_author_2 | McINTYRE, P. B. RODRIGUES, C. A. LENNARD-JONES, J. E. BARRISON, I. G. WALKER, J. G. BARON, J. H. THORNTON, P. C. |
| shingle_author_3 | McINTYRE, P. B. RODRIGUES, C. A. LENNARD-JONES, J. E. BARRISON, I. G. WALKER, J. G. BARON, J. H. THORNTON, P. C. |
| shingle_author_4 | McINTYRE, P. B. RODRIGUES, C. A. LENNARD-JONES, J. E. BARRISON, I. G. WALKER, J. G. BARON, J. H. THORNTON, P. C. |
| shingle_catch_all_1 | McINTYRE, P. B. RODRIGUES, C. A. LENNARD-JONES, J. E. BARRISON, I. G. WALKER, J. G. BARON, J. H. THORNTON, P. C. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine Blackwell Publishing Ltd Balsalazide (BSZ) is a pro-drug which releases 5-aminosalicylic acid (5ASA) and 4-aminobenzoyl-β-alanine (an inert carrier) in the colon of various species including man. BSZ was compared with sulphasalazine (SASP) (both 1 g b.d. orally) in the maintenance of remission in patients with ulcerative colitis (UC). Seventy-nine patients (5.3 male, 26 female), mean age 49 years (range 19–79 years), with UC were randomly allocated to either treatment (41 BSZ, 38 SASP) for 6 months. The groups were similar in respect of age, sex, duration and extent of disease. Seven patients defaulted (3 BSZ, 4 SASP) leaving 38 on BSZ and 34 on SASP. Two male patients, both receiving SASP, were withdrawn because of severe side-effects. One of these patients, with an exfoliative rash, was maintained satisfactorily on open BSZ. Remission rates at 6 months (51% BSZ, 63% SASP) were not significantly different (life-table analysis P 〈 0.1). Twelve patients (15%) reported troublesome side-effects (2 BSZ 5%, 10 SASP 26%, P= 0.017 Fisher Exact Test). Mean haemoglobin concentrations, similar on entry, increased after 6 months with BSZ (0.2 g/dl) but decreased with SASP (0.5 g/dl) (P 〈 0.0002). BSZ was not significantly different from SASP in maintaining remission in patients with UC but had fewer side-effects. 1365-2036 13652036 |
| shingle_catch_all_2 | McINTYRE, P. B. RODRIGUES, C. A. LENNARD-JONES, J. E. BARRISON, I. G. WALKER, J. G. BARON, J. H. THORNTON, P. C. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine Blackwell Publishing Ltd Balsalazide (BSZ) is a pro-drug which releases 5-aminosalicylic acid (5ASA) and 4-aminobenzoyl-β-alanine (an inert carrier) in the colon of various species including man. BSZ was compared with sulphasalazine (SASP) (both 1 g b.d. orally) in the maintenance of remission in patients with ulcerative colitis (UC). Seventy-nine patients (5.3 male, 26 female), mean age 49 years (range 19–79 years), with UC were randomly allocated to either treatment (41 BSZ, 38 SASP) for 6 months. The groups were similar in respect of age, sex, duration and extent of disease. Seven patients defaulted (3 BSZ, 4 SASP) leaving 38 on BSZ and 34 on SASP. Two male patients, both receiving SASP, were withdrawn because of severe side-effects. One of these patients, with an exfoliative rash, was maintained satisfactorily on open BSZ. Remission rates at 6 months (51% BSZ, 63% SASP) were not significantly different (life-table analysis P 〈 0.1). Twelve patients (15%) reported troublesome side-effects (2 BSZ 5%, 10 SASP 26%, P= 0.017 Fisher Exact Test). Mean haemoglobin concentrations, similar on entry, increased after 6 months with BSZ (0.2 g/dl) but decreased with SASP (0.5 g/dl) (P 〈 0.0002). BSZ was not significantly different from SASP in maintaining remission in patients with UC but had fewer side-effects. 1365-2036 13652036 |
| shingle_catch_all_3 | McINTYRE, P. B. RODRIGUES, C. A. LENNARD-JONES, J. E. BARRISON, I. G. WALKER, J. G. BARON, J. H. THORNTON, P. C. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine Blackwell Publishing Ltd Balsalazide (BSZ) is a pro-drug which releases 5-aminosalicylic acid (5ASA) and 4-aminobenzoyl-β-alanine (an inert carrier) in the colon of various species including man. BSZ was compared with sulphasalazine (SASP) (both 1 g b.d. orally) in the maintenance of remission in patients with ulcerative colitis (UC). Seventy-nine patients (5.3 male, 26 female), mean age 49 years (range 19–79 years), with UC were randomly allocated to either treatment (41 BSZ, 38 SASP) for 6 months. The groups were similar in respect of age, sex, duration and extent of disease. Seven patients defaulted (3 BSZ, 4 SASP) leaving 38 on BSZ and 34 on SASP. Two male patients, both receiving SASP, were withdrawn because of severe side-effects. One of these patients, with an exfoliative rash, was maintained satisfactorily on open BSZ. Remission rates at 6 months (51% BSZ, 63% SASP) were not significantly different (life-table analysis P 〈 0.1). Twelve patients (15%) reported troublesome side-effects (2 BSZ 5%, 10 SASP 26%, P= 0.017 Fisher Exact Test). Mean haemoglobin concentrations, similar on entry, increased after 6 months with BSZ (0.2 g/dl) but decreased with SASP (0.5 g/dl) (P 〈 0.0002). BSZ was not significantly different from SASP in maintaining remission in patients with UC but had fewer side-effects. 1365-2036 13652036 |
| shingle_catch_all_4 | McINTYRE, P. B. RODRIGUES, C. A. LENNARD-JONES, J. E. BARRISON, I. G. WALKER, J. G. BARON, J. H. THORNTON, P. C. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine Blackwell Publishing Ltd Balsalazide (BSZ) is a pro-drug which releases 5-aminosalicylic acid (5ASA) and 4-aminobenzoyl-β-alanine (an inert carrier) in the colon of various species including man. BSZ was compared with sulphasalazine (SASP) (both 1 g b.d. orally) in the maintenance of remission in patients with ulcerative colitis (UC). Seventy-nine patients (5.3 male, 26 female), mean age 49 years (range 19–79 years), with UC were randomly allocated to either treatment (41 BSZ, 38 SASP) for 6 months. The groups were similar in respect of age, sex, duration and extent of disease. Seven patients defaulted (3 BSZ, 4 SASP) leaving 38 on BSZ and 34 on SASP. Two male patients, both receiving SASP, were withdrawn because of severe side-effects. One of these patients, with an exfoliative rash, was maintained satisfactorily on open BSZ. Remission rates at 6 months (51% BSZ, 63% SASP) were not significantly different (life-table analysis P 〈 0.1). Twelve patients (15%) reported troublesome side-effects (2 BSZ 5%, 10 SASP 26%, P= 0.017 Fisher Exact Test). Mean haemoglobin concentrations, similar on entry, increased after 6 months with BSZ (0.2 g/dl) but decreased with SASP (0.5 g/dl) (P 〈 0.0002). BSZ was not significantly different from SASP in maintaining remission in patients with UC but had fewer side-effects. 1365-2036 13652036 |
| shingle_title_1 | Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine |
| shingle_title_2 | Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine |
| shingle_title_3 | Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine |
| shingle_title_4 | Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine |
| sigel_instance_filter | dkfz geomar wilbert ipn albert |
| source_archive | Blackwell Publishing Journal Backfiles 1879-2005 |
| timestamp | 2024-05-06T08:10:55.562Z |
| titel | Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine |
| titel_suche | Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine |
| topic | WW-YZ |
| uid | nat_lic_papers_NLZ239091507 |